Mosaic ImmunoEngineering Inc. is a development-stage biotechnology company focused on advancing and commercializing our proprietary immunostimulatory nanoparticle technology.

 

Our lead canine in situ vaccine candidate, MIE-201, was carefully selected through preclinical testing. Data from numerous mouse tumor models and in companion dogs with naturally occurring tumors show the ability of intratumoral (“IT”) administration of MIE-201 to result in anti-tumor effects in treated tumors and systemically at other sites of disease through immune activation. MIE-201 is based on a plant virus that is not infectious, but is recognized as foreign by the immune system.

 

Mosaic is finalizing plans to evaluate MIE-201 in additional canine oncology studies and is currently assessing potential strategic partners to assist in the advancement of the program.

 

The science supporting MIE-201 was the result of over twenty million dollars in research funding and has been widely published in leading peer-reviewed scientific journals.